The lysine 27 to methionine substitution in histone variant H3.3 (H3.3-K27M) is the most common mutation in pediatric high grade gliomas. Recent studies have demonstrated that this mutation leads to a global reduction of H3K27 trimethylation in a dominant manner by sequestering an enzymatic subunit of the polycomb repressive complex…
New Grant Application: High-throughput sequencing of cancer patient’s genomes has enabled the identification of genomic alterations underlying the human disease. By this technology driver mutations of high grade gliomas, an aggressive kind of brain tumor in children, have been recently described. The most prominent recurrent mutations where found in four…
Progress Update from 2nd year: 9/2012-8/2014 The Childhood Brain Tumor Foundation funded project, Novel Agent for Pediatric Glioblastomas (pGBMs), headed by Dr. Rheal Towner at the Oklahoma Medical Research Foundation, is assessing a novel agent, Oklahoma Nitrone 007 (OKN-007), in pre-clinical mouse models for pediatric glioblastomas (pGBs). Patient-derived cells, which…
Progress Update from 1st year: 8/1/2014-7/30/2016 Millions of cells are formed every day in the developing brain of children. Medulloblastoma, the most common and ag-gressive form of pediatric brain tumor, occurs when the proliferation of cells in the cerebellum becomes uncontrolled, The Notch path-way is a key mechanism that governs…
Progress Update: 9/2012-8/2014 We have completed the initial set of studies to examine the role of MPS1 in controlling medulloblastoma cell division and validated a therapeutic target. We demonstrated that MPS1 is critical for cell division of tumor cells and both genetic and chemi-cal inhibition of MPS1. Several 1st generation…
Page 1 of 2

Thanks to Our Sponsors